Hadassah

Placental Cells Found to Have Potential to Mitigate Acute Radiation Syndrome

Monday, Oct 24 2011

"In pre-clinical studies," notes Prof. Raphael Gorodetsky, head of the Biotechnology and Radiobiology Laboratory at the Sharrett Institute of Oncology at Hadassah University Medical Center, "we found that placental-derived cells potentially have the ability to increase the survival rate of animals following exposure to lethal doses of total body irradiation."

These placental (PLX) cells, developed by Pluristem Therapeutics Inc., treat life-threatening complications associated with Acute Radiation Syndrome (ARS).

During the studies, animals were injected intravenously with either PLX cells or a placebo, on the day after being exposed to lethal doses of radiation. Nine days following treatment with the PLX cells, the animals' bone marrow and spleen were examined for signs of hematopoietic (blood forming) tissue. On day 23, bone marrow and blood samples were examined in the surviving animals. Overall survival and body weight changes were also monitored. The researchers found in the animals treated with the PLX cells:

  • an up to four-fold increase in the survival rate accompanied by a corresponding weight regain
  • an increase in red-cell count on days 21-23
  • an elevated number of hematopoietic colonies on day 9

Over the next few months, Prof. Gorodetsky and his team will focus on better understanding the PLX cells' mechanism of action as an "off the shelf" post radiation treatment, which could potentially be used in the future for treating ARS patients.

"While our experiments using PLX cells in treating radiation exposure are ongoing and still evolving, these initial data are very encouraging," said Zami Aberman, Chairman and Chief Executive Officer of Pluristem. "PLX cells as a sole treatment may potentially enhance the survival of lethally irradiated individuals. Moreover, since our previous work indicated that PLX cells can enhance the engraftment of hematopoietic stem cells from cord blood, we can offer a multifaceted approach to reduce and treat the destruction of bone marrow that occurs following exposure to high-dose ionizing radiation. Stockpiled PLX cells can be administered acutely and as a bridging therapy to protect the bone marrow."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Feb 14 2018

Student with MS Running the Jerusalem Marathon to Support Hadassah’s MS Program

Thanks to his physicians at the Hadassah Medical Center, Dov Guggenheim, who was diagnosed with Multiple Sclerosis (MS) in 2015, has gone from “depressed to optimistic, paralyzed to athletic, and, most important, hopeless to hopeful.”

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Texas Tropical Disease Expert Meets with Hadassah Infectious Disease Specialists

Dr. Peter Jay Hotez, renowned professor in the Departments of Pediatrics and Molecular Virology and Microbiology at Houston (Texas) Baylor College of Medicine and Dean of its National School of Tropical Medicine, met with two Hadassah Medical Organization infectious disease specialists to discuss regional cooperation in fighting tropical diseases, such as the now-infamous Zika virus and leishmaniosis, which is contracted from sand flies.

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Large Hadassah Study Identifies Predictor of Greater Risk of End-Stage Renal Disease

The findings of a nationwide study of over a million and a half Israeli adolescents, conducted by researchers at the Hadassah-Hebrew University Braun School of Public Health and Community Medicine, suggest that kidney disease in childhood is associated with a significantly increased risk of end-stage renal disease (ESRD) in adulthood, even if kidney function seems normal in adolescence.

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Israeli Start-up’s Algorithm Predicts Which Diabetic Patients Will Suffer Kidney Dysfunction Within One Year

The Israeli start-up Medial EarlySign has created a machine-learning-based model that has proven to identify diabetic patients who are at the highest risk for experiencing renal dysfunction within one year.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More